JAMA Oncology : Neratinib vs Trastuzumab for Untreated Metastatic ERBB2-Positive Breast Cancer

Interview with Ahmad Awada, MD, PhD, author of Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer: The NEfERT-T Randomized Clinical Trial, and Mark D. Pegram, MD, author of Neratinib in ERBB2-Positive Brain Metastases

Source: JAMA Specialty Journals Author Interviews - April 14, 2016 Category: Journals (General) Authors: The JAMA Network Source Type: podcasts